Xalud Therapeutics
Phase 2Xalud Therapeutics is a clinical-stage biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $119M
About
Xalud Therapeutics is a clinical-stage biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation.
Biologics
Funding History
3Total raised:$119M
Series C$64MMay 15, 2022
Series B$35MSep 15, 2020
Series A$20MMar 15, 2018